Shared on 01 Nov 25
Fair value Increased 3.11%Eli Lilly’s fair value estimate has increased from $891.62 to $919.33. This reflects analysts' upward price target revisions following stronger than expected quarterly results and an improved earnings outlook.
Shared on 04 Sep 25
Fair value Increased 0.35%Emerging Markets And Digital Health Will Fuel Future Expansion
Analysts remain bullish on Eli Lilly due to strong Phase 3 obesity data and pipeline momentum, outweighing isolated setbacks in heart failure, and have maintained the consensus price target at $888.52. Analyst Commentary Bullish analysts highlight the strong Phase 3 data for orforglipron in obesity and diabetes (ATTAIN-1 and ATTAIN-2), demonstrating efficacy and tolerability at or above expectations, positioning Eli Lilly favorably versus oral and injectable competitors.
Shared on 07 May 25
Fair value Decreased 18%Emerging Markets And Digital Health Will Fuel Future Expansion
Shared on 30 Apr 25
Fair value Decreased 1.51%Phase III Trials And Manufacturing Will Unlock Future Opportunities
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 23 Apr 25
Fair value Decreased 0.025%Phase III Trials And Manufacturing Will Unlock Future Opportunities
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 16 Apr 25
Fair value Decreased 0.26%Phase III Trials And Manufacturing Will Unlock Future Opportunities
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 09 Apr 25
Fair value Increased 0.099%Phase III Trials And Manufacturing Will Unlock Future Opportunities
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 02 Apr 25
Fair value Increased 8.97%Phase III Trials And Manufacturing Will Unlock Future Opportunities
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 26 Mar 25
Fair value Decreased 0.11%Phase III Trials And Manufacturing Will Unlock Future Opportunities
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 19 Mar 25
Fair value Increased 0.38%Phase III Trials And Manufacturing Will Unlock Future Opportunities
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 17 Mar 25
Phase III Trials And Manufacturing Will Unlock Future Opportunities
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 10 Mar 25
Fair value Increased 5.68%Phase III Trials And Manufacturing Will Unlock Future Opportunities
AnalystConsensusTarget has increased shares outstanding growth rate from -0.0% to -0.0%.